NCCN GUIDELINES® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines

Margaret von Mehren, John M. Kane, Richard F. Riedel, Jason K. Sicklick, Seth M. Pollack, Mark Agulnik, Marilyn M. Bui, Janai Carr-Ascher, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Ricardo J. Gonzalez, Ashley Holder, Jade Homsi, Vicki Keedy, Ciara M. Kelly, Edward Kim, David Liebner, Martin McCarterSean V. McGarry, Nathan W. Mesko, Christian Meyer, Alberto S. Pappo, Amanda M. Parkes, Ivy A. Petersen, Matthew Poppe, Scott Schuetze, Jacob Shabason, Matthew B. Spraker, Melissa Zimel, Mary Anne Bergman, Hema Sundar, Lisa E. Hang

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)1204-1214
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume20
Issue number11
DOIs
StatePublished - Nov 2022

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'NCCN GUIDELINES® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this